Charlie Fehl, a University of Kansas graduate student in medicinal chemistry, is working to find more selective and effective treatments for prostate cancer. The current standard of treatment, Abiraterone, was approved in 2011. However, the drug has debilitating side effects. Fehl uses an advanced understanding of tumor biology to learn ways to limit the growth of prostate cancer tumors. Those efforts include the study of the biochemical crystal structures of the enzyme that creates the chemical signal that fuels prostate cancer growth. The crystals were grown in the COBRE-PSF Protein Structure Core Laboratory headed by Director Scott Lovell.
Fehl’s research was featured in February 2013 at the Capitol Graduate Research Summit in Topeka, Kan. This event provides an opportunity for graduate students from KU, KU Medical Center, and other universities in Kansas to showcase for legislators Topeka the latest research under way in the state. His interview is featured in a YouTube video.
Edited March 29, 2013 article from the KU Office of Public Affairs